Objective: To investigate the relationship between Hashimoto’s thyroiditis (HT) and papillary thyroid carcinoma (PTC). Methods: The clinical data of 495 patients who underwent surgical treatment and diagnosed as PTC by postoperative pathological examination from January 2010 to May 2015 were reviewed. The clinicopathologoic characteristics between patients with and without concomitant HT were compared. Results: Among the 495 PTC patients, 108 cases (21.81%) had concomitant HT. Results of univariate analysis showed that in PTC patients with concomitant HT compared with those without HT, female cases were more frequent (90.7% vs. 71.6%), the preoperative levels of thyroid stimulating hormone (4.04 μIU/mL vs. 2.76 μIU/mL) and thyroid peroxidase antibody (TPOAb) (94.31 IU/mL vs. 33.65 IU/mL) were elevated, maximum tumor diameter was shorter (1.10 cm vs. 1.31 cm) and the number of cases with early clinical stage was increased (stage I: 87.1% vs. 76.8%), and all differences had statistical significance (all P<0.05). Logistic regression analysis showed that gender, TSH level, TPOAb level and clinical stage were independent predictors for PTC combined with HT (all P<0.05). Conclusion: PTC patients with concomitant HT present with female predominance, earlier clinical stage, and small size, suggesting that the combined HT may not increase the invasiveness of PTC, and may have a relatively good prognosis. However, the TSH level is increased in patients with concomitant HT, which suggests that HT may be one of the risks for PTC.